Novo Nordisk’s Ozempic, grappling with Eli Lilly’s Trulicity for supremacy of the GLP-1 diabetes market, hit a snag last year when the FDA refused to review a new dosing regimen over the need for more ...

The US Food and Drug Administration (FDA) approved two additional doses of Eli Lilly and Company's Trulicity (dulaglutide). The approval expands the label of once-weekly Trulicity to include 3.0 mg ...